Myriad Genetics Inc (NAS:MYGN)
$ 25.29 0.7 (2.84%) Market Cap: 2.29 Bil Enterprise Value: 2.33 Bil PE Ratio: 0 PB Ratio: 3.01 GF Score: 76/100

Castle Biosciences Inc to Acquire Myriad myPath® Laboratory Transcript

Apr 27, 2021 / 11:30AM GMT
Release Date Price: $30.63 (+1.09%)
Operator

Good morning, and welcome to Castle Biosciences myPath Melanoma conference call. As a reminder, today's call is being recorded. We will begin today's call with opening remarks and introductions, followed by a question-and-answer session regarding the transaction.

I would like to turn the call over to Frank Stokes, CFO. Please go ahead.

Frank Stokes
Castle Biosciences, Inc. - CFO

Thank you, operator. Good morning, everyone. Welcome to the call. Joining me today is Castle's Founder, President and Chief Executive Officer, Derek Maetzold.

Information recorded on this call speaks only as of today, April 27, 2021. Therefore, if you are listening to the replay or reading the transcript of this call, any time-sensitive information may no longer be accurate. A recording of today's call will be available on the Investor Relations page of the company's website for approximately 3 weeks.

Before we begin, I'd like to remind you that some of the information discussed today may contain projections or other forward-looking statements regarding

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot